United States Type 2 Diabetes Market to Reach $62.59 Billion by 2031, Driven by GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Advanced Digital Health Solutions | Abbott, Medtronic, Dexcom Inc.

The Global Type 2 Diabetes Market reached US$ 33.07 billion in 2023 and is expected to reach US$ 62.59 billion by 2031 growing with a CAGR of 8.3% during the forecast period 2024-2031.

The type 2 diabetes market encompasses drugs, devices, and management solutions for patients with insulin resistance and high blood sugar levels. Treatments include oral hypoglycemics, insulin therapy, and continuous glucose monitoring systems. Rising prevalence due to obesity and sedentary lifestyles fuels market growth. Innovations in drug formulations and digital health solutions enhance patient compliance. Government initiatives and awareness campaigns further expand the market.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Type 2 Diabetes Market Landscape:- https://datamintelligence.com/download-sample/type-2-diabetes-market?rk

☛ Type 2 Diabetes Market Recent Developments 2025:

United States: Recent Industry Developments

✅ In August 2025, Novo Nordisk launched semaglutide 2.0 mg for Type 2 diabetes management, demonstrating improved HbA1c control and weight reduction in adults with obesity and T2D.

✅ In July 2025, Eli Lilly received FDA approval for tirzepatide, a dual GIP/GLP-1 receptor agonist, showing significant efficacy in glycemic control and cardiovascular risk reduction in T2D patients.

✅ In June 2025, Merck & Co. initiated Phase 3 trials for a once-weekly oral GLP-1 receptor agonist, aiming to provide a non-injectable option for patients struggling with daily therapy adherence.

Europe: Recent Industry Developments

✅ In July 2025, Sanofi expanded access to insulin glargine biosimilars across European markets, improving affordability and patient adherence in T2D management.

✅ In June 2025, Novo Nordisk partnered with NHS UK to implement digital diabetes management programs, integrating continuous glucose monitoring with AI-driven insights for personalized care.

✅ In May 2025, Boehringer Ingelheim announced positive Phase 3 results for its SGLT2 inhibitor combination therapy, reducing cardiovascular and renal complications in T2D patients.

Japan: Recent Industry Developments

✅ In July 2025, Takeda Pharmaceutical launched GLP-1 analog therapy targeting Japanese adults with T2D, emphasizing cardiovascular benefits and glycemic control.

✅ In June 2025, Astellas Pharma initiated a nationwide program integrating digital health tools for T2D management, focusing on patient adherence and lifestyle monitoring.

✅ In May 2025, Eli Lilly Japan expanded access to tirzepatide for patients with T2D and obesity, supporting early intervention strategies and improved clinical outcomes.

☛ Type 2 Diabetes Market Trends:

Rising demand for oral hypoglycemics, GLP-1 receptor agonists, and SGLT2 inhibitors is notable. Continuous glucose monitoring and digital health platforms enhance disease management. Lifestyle interventions and combination therapies are increasingly integrated. Precision medicine approaches for patient-specific treatment are emerging. Government initiatives and awareness campaigns drive diagnosis and treatment adoption.

Recent Pipelines:

Novel GLP-1/GIP dual agonists and oral insulin formulations are in advanced trials. SGLT2 inhibitors with cardio-renal benefits are under evaluation. Digital therapeutics and AI-powered glucose monitoring platforms are emerging. Combination therapies targeting multiple metabolic pathways are progressing. Gene therapy approaches for beta-cell function restoration are being researched.

☛ Type 2 Diabetes Market Competitve Landscape:

Abbott, Medtronic, Dexcom, Inc., AstraZeneca, TheracosBio, LLC, Boehringer Ingelheim International GmbH, Eli Lilly and Company., Novo Nordisk A/S, Merck & Co., Inc., and Pfizer Inc. among others.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/type-2-diabetes-market

☛ Segment Covered in the Type 2 Diabetes Market:

By Drug Type: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors, Alpha-glucosidase Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists), Sodium-glucose Transporter 2 (SGLT2) Inhibitors, Meglitinides, Sulfonylureas, Thiazolidinediones, Biguanides (Metformin), Bile Acid sequestrants (Colesevelam), Amylin Mimetics (Pramlintide).

By Gender: Male, Female.

By Age Group: Up to 19 years, 20 - 65 years, Above 65 years.

By Route of Administration: Oral, Parenteral.

By Application: Glycemic Control, Cardiovascular Safety, Hypoglycemia Avoidance, Others.

By Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Type 2 Diabetes Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=type-2-diabetes-market

☛ Regional Analysis for Type 2 Diabetes Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

☛ Frequently asked questions:

➠ What is the global sales, production, consumption, import, and export value of the Type 2 Diabetes Market?
➠ Who are the key global manufacturers, and what is their operational performance?
➠ What are the major opportunities and threats in the global Type 2 Diabetes Market?
➠ Which product types or end-users show the most growth potential and market share?
➠ What challenges and constraints are impacting the Type 2 Diabetes Market?
➠ What sales, marketing, and distribution channels are used globally?

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.